Pfizer Inc. (NYSE:PFE) Shares Acquired by KLCM Advisors Inc.

KLCM Advisors Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 75.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 173,793 shares of the biopharmaceutical company’s stock after acquiring an additional 74,487 shares during the period. KLCM Advisors Inc.’s holdings in Pfizer were worth $5,004,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PFE. Moneta Group Investment Advisors LLC increased its holdings in shares of Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Norges Bank bought a new position in Pfizer in the 4th quarter valued at about $3,150,472,000. Charles Schwab Investment Management Inc. grew its position in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley grew its position in Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pfizer in the 1st quarter valued at about $311,238,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Stock Down 0.8 %

PFE traded down $0.22 during midday trading on Wednesday, hitting $25.69. 28,885,313 shares of the company’s stock traded hands, compared to its average volume of 33,467,946. The company has a market cap of $145.47 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The stock’s fifty day simple moving average is $27.23 and its 200-day simple moving average is $28.79. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a one year low of $25.61 and a one year high of $41.33.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.